Oreola Donini, Ph.D., has been appointed vice president of Preclinical R&D at Soligenix, Inc. Dr. Donini has more than 13 years experience in drug discovery and preclinical development with start-up biotechnology companies. Dr. Donini previously worked with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer, and supportive care.
Dr. Donini is a co-inventor and leader of the SGX94 innate defense regulator technology, developed by Inimex Pharmaceuticals and subsequently acquired by Soligenix. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment.
"As we continue to execute on our growth strategy, we are clearly building momentum and the talent we are attracting is an absolute reflection of our solid progress to date," said Christopher J. Schaber, PhD, president and chief executive officer of Soligenix. "We are delighted to welcome Oreola to our team, as she will leverage her extensive preclinical and early stage clinical drug development expertise in leading our SGX94, gastrointestinal acute radiation syndrome (GI ARS) and melioidosis programs. Her preclinical experience in the areas of infectious disease, tissue damage and innate immunity will be instrumental to us as we advance OrbeShield in GI ARS, and SGX94 to Phase II completion in oral mucositis."